Figure 7 Plasma cytokine and growth factor levels in adults and elderly: Cytokine levels in plasma specimens of adults and elderly were measured using a multiplex biochip array system, Evidence Investigator TM (Randox laboratories Ltd, Crumlin, UK). The bar diagram shows mean with standard error of mean for: (A) TH-1 Cytokines [IL-2, IL-8, IL-1a, IL-1b, IFN-c and TNF-a], (B) TH-2 Cytokines [IL-4, IL-6 and IL-10] and (C) Growth Factors (MCP-1, VEGF and EGF). Significant differences were observed in the concentration of plasma levels of IL-1b, IL-2, IFN-c, TNF-a, IL-6, MCP-1 and EGF between the elderly participants and adults. Source: Valiathan, 2016.

Lymphocytes, neutrophils and IL-6 and the “Effects of Ageing on the Immune System”.

Valiathan et al., 2016 (1), published an informative article on the aging of the immune system. The authors found that lymphocytes in the elderly, 70 to 92 years, were lower than in adults, 21 to 50 years. Neutrophils in the elderly were elevated. Cytokine IL-6 was also elevated in the elderly. Levels of lymphocytes, neutrophils, and IL-6 all have strong predictive value in the outcome of COVID-19.

The brainwashed masses are ready to inject themselves with anything. But will vaccines work in those who are in the high-risk group, that is, people aged 70 and older? It is unlikely. According to a 2006 study by Corsini et al., the currently available influenza vaccines do not work in 70% of those aged 70 to 80 do develop antibodies after a flu vaccination. Among those aged 80 and above, 90% do not develop antibodies after a flu vaccine administration.

COVID-19 vaccines are unlikely to protect those who are at a higher risk. A 2006 study: Vaccines fail to generate protective immunity in 50% to 90% of older individuals.

Seroconversion after a vaccine is 50% from 60 to 70 years old, 31% from 70 to 80 years old, and only 11% after the age of 80.
Conclusions: Billions are being spent on COVID-19 vaccines that are unlikely to work in the highest-risk group, those aged 70 and above.